Latest Annexon Biosciences News & Updates

See the latest news and media coverage for Annexon Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Annexon Biosciences

Developer of C1q inhibitors for complement-driven diseases

annexonbio.com
Headquarters
South San Francisco, United States
Founded year
2011
Company type
Public company
Number of employees
100–200

Last updated

Latest news about Annexon Biosciences

In short: Annexon Biosciences submitted a marketing application for tanruprubart and advanced its Phase 3 trial for vonaprument amidst annual losses.

Company announcements

  • Annexon Biosciences

    Annexon reports Q1 2026 financial results

    Cash at $225M extends runway to H2 2027. Portfolio updates include Phase 3 GA data in Q4 2026, GBS BLA in 2026, ANX1502 POC in 2026.

  • Annexon Biosciences

    Annexon presents Phase 3 results at AAN Meeting

    Henk-André Kroon presents data on tanruprubart for Guillain-Barré syndrome in Chicago. GBS is a rapid-onset neuromuscular emergency with unmet needs.

  • Annexon Biosciences

    Annexon reports Q4 and year-end 2025 financial results

    Highlights portfolio progress including ARCHER II data expected Q4 2026, tanruprubart MAA filed, $238.3M cash runway to H2 2027. Net loss $48.3M for Q4, $208.5M for year.

  • Annexon Biosciences

    Annexon highlights 2026 milestones for immunotherapies

    Tanruprubart MAA filed for GBS; vonaprument Phase 3 data for GA expected H2 2026; ANX1502 POC data anticipated. Funds into 2027.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Annexon Biosciences

Track Annexon Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.